Infectious Diseases
Page 1 • 6 itemsGlobal pharma infectious disease market intelligence: track R&D, regulatory approvals, and investment trends for novel antivirals, antibacterials, and vaccines.
FDA Grants Priority Review for Gilead's Bictegravir Plus Lenacapavir HIV Treatment Combination
Gilead Sciences receives FDA priority review for novel once-daily HIV treatment combining bictegravir and lenacapavir, potentially the smallest single-tablet regimen.
Emergent BioSolutions Partners with Substipharm for $34.5M Japanese Encephalitis Vaccine Manufacturing Deal
Emergent BioSolutions announces $34.5M partnership with Substipharm Biologics to manufacture IMOJEV Japanese encephalitis vaccine for U.S. government distribution.
Novartis Coartem Baby Receives WHO Prequalification as First Malaria Treatment for Newborns
WHO prequalifies Novartis Coartem Baby, the first malaria treatment for newborns and young infants, enabling global procurement and access.
FDA Approves Merck's IDVYNSO: First Non-INSTI, Tenofovir-Free Two-Drug HIV Treatment
FDA approves Merck's IDVYNSO (doravirine/islatravir), the first non-INSTI, tenofovir-free two-drug HIV regimen showing non-inferior efficacy to BIKTARVY.
Aicuris Receives FDA Priority Review for Pritelivir, Novel Herpes Treatment for Immunocompromised Patients
FDA grants Priority Review for Aicuris' pritelivir NDA, targeting resistant herpes infections in immunocompromised patients with Q4 2026 PDUFA date.
Elion Therapeutics Launches Phase 2 Trial for Turletricin (EL219) in Invasive Mold Infections
Elion Therapeutics initiates Phase 2 clinical trial for turletricin (EL219) targeting invasive mold infections, with FDA Fast Track and QIDP designations.